このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Dermoscopy and UVFD in Differentiating Palmoplantar Psoriasis and Palmoplantar Eczema

2026年5月29日 更新者:Didem Kacan、Istanbul Training and Research Hospital

Comparative Evaluation of Polarized Dermoscopy and Ultraviolet-Induced Fluorescence Dermoscopy in the Differential Diagnosis of Palmoplantar Psoriasis and Palmoplantar Eczema

Palmoplantar psoriasis and palmoplantar eczema are chronic inflammatory skin diseases that may show similar findings on the palms and soles, such as redness, scaling, thickening of the skin, fissures, itching, and burning. Because these conditions can look alike, distinguishing between them in routine clinical practice may be difficult.

This prospective, single-center observational study was designed to compare polarized dermoscopic and ultraviolet-induced fluorescence dermoscopic (UVFD) findings in adult patients with palmoplantar psoriasis and palmoplantar eczema. A total of 81 patients aged 18 years and older were included: 41 patients with clinically and/or histopathologically confirmed palmoplantar plaque psoriasis and 40 patients with palmoplantar eczema.

Dermoscopic and UVFD images were evaluated to identify vascular, scaling, surface, and fluorescence-related features that may help differentiate palmoplantar psoriasis from palmoplantar eczema. The study aims to assess whether these non-invasive imaging methods can provide additional diagnostic clues to support clinical evaluation.

調査の概要

状態

積極的、募集していない

詳細な説明

This prospective, single-center, observational comparative study was designed to evaluate polarized dermoscopic and ultraviolet-induced fluorescence dermoscopic (UVFD) findings in the differential diagnosis of palmoplantar psoriasis and palmoplantar eczema.

Adult patients aged 18 years and older with clinically and/or histopathologically confirmed palmoplantar plaque psoriasis or palmoplantar eczema were enrolled. Patients with recent topical or systemic treatment, positive fungal examination, palmoplantar pustulosis, other confounding palmoplantar dermatoses, malignancy or immunosuppressive conditions, pregnancy, lactation, non-specific histopathological findings, or histopathological findings inconsistent with the clinical diagnosis were excluded.

Demographic and clinical characteristics, lesion localization, symptom profile, relevant dermatological history, nail involvement, and disease severity parameters were recorded. Standardized polarized dermoscopic and UVFD images were obtained using a handheld dermoscope (DermLite DL5, 3Gen Inc., San Juan Capistrano, CA, USA). Imaging was performed under standardized conditions, and predefined dermoscopic and UVFD parameters relevant to inflammatory palmoplantar dermatoses were systematically evaluated.

In polarized dermoscopy, vascular morphology and distribution, scale color and distribution, background color, yellow-brown globules, yellow-orange structureless areas, yellow-orange crusts, and hemorrhage within scales were assessed. In UVFD, scale distribution, scale pattern, dominant fluorescence color, additional fluorescence color, and white-yellow fluorescent foci were evaluated. Image assessments were performed by independent dermatologists blinded to the clinical diagnosis.

The main objective of the study is to compare polarized dermoscopic and UVFD findings between palmoplantar psoriasis and palmoplantar eczema and to identify features that may support the clinical differentiation of these overlapping palmoplantar dermatoses. The study does not assign any treatment or intervention; all imaging procedures are non-invasive and performed for observational diagnostic evaluation.

研究の種類

観察的

入学 (実際)

81

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Istanbul
      • Istanbul、Istanbul、トルコ(Türkiye)、34000
        • Istanbul Training and Research Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

非確率サンプル

調査対象母集団

A total of 81 adult patients aged 18 years and older with clinically and/or histopathologically confirmed palmoplantar plaque psoriasis or palmoplantar eczema were included. Participants were recruited from the dermatology outpatient clinic of a tertiary care training and research hospital.

説明

Inclusion Criteria:

  • Age 18 years or older.
  • Clinical diagnosis of palmoplantar psoriasis or palmoplantar eczema involving the palms and/or soles.
  • For the palmoplantar psoriasis group: presence of sharply demarcated erythematous and scaly plaques on the palms and/or soles, with diagnosis confirmed clinically and/or histopathologically.
  • In clinically uncertain palmoplantar psoriasis cases, at least one supporting feature such as psoriatic lesions outside the palmoplantar area, psoriatic nail involvement, psoriatic arthritis, personal history of psoriasis, or family history of psoriasis.
  • For the palmoplantar eczema group: presence of chronic or recurrent palmoplantar eczema with hyperkeratotic and/or fissured palmoplantar plaques, with diagnosis confirmed clinically and/or histopathologically.
  • Ability and willingness to provide written informed consent.

Exclusion Criteria:

  • Age younger than 18 years.
  • Presence of another palmoplantar dermatosis that may interfere with the diagnosis of palmoplantar psoriasis or palmoplantar eczema.
  • Histopathological findings inconsistent with the clinical diagnosis, when histopathological examination was performed.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
Palmoplantar Psoriasis
Patients with clinically and/or histopathologically confirmed palmoplantar psoriasis
Palmoplantar Eczema
Patients with clinically and/or histopathologically confirmed palmoplantar eczema

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of Participants With Findings on the Predefined Polarized Dermoscopic Feature Checklist Assessed Using DermLite DL5
時間枠:At baseline / single study visit

Name of measurement: Predefined Polarized Dermoscopic Feature Checklist. Measurement tool: standardized polarized dermoscopic images obtained with a DermLite DL5 handheld dermoscope. Unit of measure: percentage of participants (%).

Standardized polarized dermoscopic images will be assessed by blinded independent dermatologists using the checklist. The checklist includes vascular morphology, vascular distribution, scale color, scale distribution, background color, yellow-brown globules, yellow-orange structureless areas, yellow-orange crusts, and hemorrhage within scales. The percentage of participants with each finding will be reported separately for the palmoplantar psoriasis and palmoplantar eczema groups.

At baseline / single study visit
Percentage of Participants With Each Predefined Ultraviolet-Induced Fluorescence Dermoscopy Feature Assessed by DermLite DL5
時間枠:At baseline / single study visit
Unit of measure: percentage of participants (%). Measurement tool: standardized ultraviolet-induced fluorescence dermoscopy (UVFD) images obtained with a DermLite DL5 handheld dermoscope and assessed by blinded independent dermatologists using a predefined UVFD feature checklist. The checklist includes UVFD scale distribution, UVFD scale pattern, dominant fluorescence color, additional fluorescence color, and white-yellow fluorescent foci. The percentage of participants with each feature will be reported and compared between the palmoplantar psoriasis and palmoplantar eczema groups.
At baseline / single study visit

二次結果の測定

結果測定
メジャーの説明
時間枠
Cohen's Kappa Coefficient for Interobserver Agreement in Binary and Nominal Dermoscopic and UVFD Feature Assessment
時間枠:At baseline / single study visit

Name of measurement: Cohen's kappa coefficient for interobserver agreement. Measurement tool: blinded independent assessment of standardized polarized dermoscopic and ultraviolet fluorescence dermoscopic images using predefined feature checklists. Unit of measure: Cohen's kappa coefficient.

Two blinded independent dermatologists will assess standardized images using predefined feature checklists. Cohen's kappa coefficient will be calculated separately for binary and nominal categorical checklist findings to evaluate interobserver agreement.

At baseline / single study visit
Quadratic Weighted Kappa Coefficient for Interobserver Agreement in Ordinal Dermoscopic and UVFD Feature Assessment
時間枠:At baseline / single study visit

Name of measurement: quadratic weighted kappa coefficient for interobserver agreement. Measurement tool: blinded independent assessment of standardized polarized dermoscopic and ultraviolet fluorescence dermoscopic images using predefined feature checklists. Unit of measure: quadratic weighted kappa coefficient.

Two blinded independent dermatologists will assess standardized images using predefined feature checklists. Quadratic weighted kappa coefficient will be calculated separately for ordinal checklist findings to evaluate interobserver agreement.

At baseline / single study visit

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年11月1日

一次修了 (実際)

2026年4月20日

研究の完了 (推定)

2026年7月31日

試験登録日

最初に提出

2026年5月8日

QC基準を満たした最初の提出物

2026年5月29日

最初の投稿 (実際)

2026年6月4日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月4日

QC基準を満たした最後の更新が送信されました

2026年5月29日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する